SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $190,241 | -30.2% | 13,102 | +0.6% | 0.00% | 0.0% |
Q2 2023 | $272,549 | +9.1% | 13,022 | +10.1% | 0.00% | 0.0% |
Q1 2023 | $249,765 | -17.0% | 11,826 | -0.0% | 0.00% | 0.0% |
Q4 2022 | $300,997 | +18.0% | 11,827 | +11.3% | 0.00% | 0.0% |
Q3 2022 | $255,000 | +30.8% | 10,626 | +4.2% | 0.00% | 0.0% |
Q2 2022 | $195,000 | -23.2% | 10,193 | -30.4% | 0.00% | 0.0% |
Q1 2022 | $254,000 | -30.8% | 14,636 | -12.8% | 0.00% | 0.0% |
Q4 2021 | $367,000 | +18.8% | 16,785 | +3.9% | 0.00% | 0.0% |
Q3 2021 | $309,000 | -11.5% | 16,151 | -20.6% | 0.00% | 0.0% |
Q2 2021 | $349,000 | +5.1% | 20,334 | +36.9% | 0.00% | 0.0% |
Q1 2021 | $332,000 | +21.6% | 14,856 | +21.0% | 0.00% | 0.0% |
Q4 2020 | $273,000 | +200.0% | 12,275 | +9.2% | 0.00% | 0.0% |
Q3 2018 | $91,000 | +4.6% | 11,240 | -8.9% | 0.00% | 0.0% |
Q2 2018 | $87,000 | -52.2% | 12,337 | -3.5% | 0.00% | 0.0% |
Q1 2018 | $182,000 | +40.0% | 12,782 | -14.1% | 0.00% | 0.0% |
Q4 2017 | $130,000 | – | 14,887 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |